| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Although the mechanisms that underlie the production of itch are poorly understood, pruritis is a significant problem associated with analgesic therapies directed at the spinal cord. We showed μ opioid receptor(MOR) agonist-evoked itch is significantly reduced in the β3 isozyme of phospholipase C(PLCβ3) mutant mice.We are presently evaluating the contribution of PLCβ3 to the pruritis produced by MOR agonist administered directly to the spinal cord.
There is little information regarding its antipruritic effects of gabapentin (GBP).Intrathecally, GBP inhibited scratching behavior induced by DAMGO without reducing analgesic effect in mice. Our results suggest that intrathecal administration of GBP can be useful in reducing pruritis, while retaining its analgesic effects. In addition, we showed GBP and NSAIDs play an important role at the spinal level, and that GBP augments the antihyperalgesic effects induced by NSAIDs through a spinal action during the postoperative pain process.
|
